Inhibikase Therapeutics (IKT) Debt Ratio (2020 - 2025)

Inhibikase Therapeutics (IKT) has reported Debt Ratio for 6 consecutive years, with 0.0 the latest figure, recorded in Q2 2025.

• In Q2 2025, Debt Ratio fell 97.52% year-over-year to 0.0; the TTM figure through Jun 2025 stood at 0.0 (down 97.52% YoY), while the FY2024 annual figure was 0.0, down 96.94% from the prior year.
• Debt Ratio eased to 0.0 in Q2 2025 per IKT's latest filing, from 0.0 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.1 in Q1 2021 and bottomed at 0.0 in Q2 2025.
• Historically, Debt Ratio has averaged 0.02 across 5 years, with a median of 0.01 in 2022.
• Annual changes were most pronounced in 2023 — Debt Ratio soared 526.92% — and 2025, when it slumped 97.52%.
• Inhibikase Therapeutics' Debt Ratio stood at 0.01 in 2021, then grew by 7.77% to 0.01 in 2022, then jumped by 526.92% to 0.04 in 2023, then tumbled by 96.94% to 0.0 in 2024, then tumbled by 61.9% to 0.0 in 2025.
• Business Quant data shows IKT's Debt Ratio at 0.0 in Q2 2025, 0.0 in Q1 2025, and 0.0 in Q4 2024.